Hematologic Disorders Education Center

Hematological disorders present an enormous set of challenges for clinicians. Healthcare providers are thankful that the treatment alternatives for these disorders are improving at a significant rate and that patient outcomes are improving as well.

The challenge for many clinicians is to keep track of the new pharmacologic approaches to treating hematological disorders. This website has been designed as a resource center for hematologists, oncologists, and other healthcare providers who are involved in the care of these patients.

FDA Alert: Split-Dosing Daratumumab Regimen Approved for Multiple Myeloma

FDA Alert: Split-Dosing Daratumumab Regimen Approved for Multiple Myeloma

The FDA has approved a new dosing regimen for daratumumab (Darzalex; Janssen) for the treatment of patients with multiple myeloma...
Breast Cancer Survivors at Risk for Hematologic Malignant Neoplasms

Breast Cancer Survivors at Risk for Hematologic Malignant Neoplasms

Breast cancer survivors have increased rates of acute myeloid leukemia and myelodysplastic syndrome compared with woman in the general population...
Ruxolitinib Reduces Thrombosis Risk, Death in PV Patients

Ruxolitinib Reduces Thrombosis Risk, Death in PV Patients

Ruxolitinib significantly reduces the risk of thrombosis and death in polycythemia vera (PV) patients who cannot tolerate or do not respond to hydroxyurea, according to a European study that compared clinical trial and real world results...
Guideline-Recommended Therapy Not Offered to Most High-Risk PV Patients

Guideline-Recommended Therapy Not Offered to Most High-Risk PV Patients

Despite guidelines that recommend cytoreductive therapy for high-risk patients with polycythemia vera (PV) the majority of these patients do not receive the therapy...
Understanding the Complex Relationship of Iron Dysregulation and PV

Understanding the Complex Relationship of Iron Dysregulation and PV

Many patients with polycythemia vera (PV) present with iron deficiency and nearly all develop iron deficiency as the disease progresses...

Loading...